ONCOLOGY CONTRACT 
MANUFACTURING

At Baxter’s manufacturing facility dedicated to oncology products in Halle/Westfalen, Germany, all of your parenteral needs are handled at one location, enabling processing solutions to fit your compound.

Your oncology products can make a difference in patients’ lives. 

Our oncology manufacturing expertise can help you make that difference.

Global Experience

More than 60 years of oncology experience manufacturing products sold worldwide including North America, South America, Europe and Asia.

Broad Expertise

Dedicated clinical through commercial production with integrated technologies and services. Specialized areas of focus include cytotoxics, highly potent compounds, biologics, lyophilized products, and antibody-drug conjugates (ADCs).

Maximizing Manufacturing Value

Baxter’s Halle facility offers state-of-the-art cGMP manufacturing, uniquely designed to deliver high-quality products with optimum efficiency and speed to market.

To discuss sterile contract manufacturing services for injectable molecules, please contact us at: 
United States: 1-800-4-BAXTER 
International: 1-224-948-4770

Go to article: Home | Waive goodbye to vaccine patentsGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: DatwylerGo to article: Datwyler Company InsightGo to article: LabcorpGo to article: Biesterfeld Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Dr. Paul LohmannGo to article: ButterworthGo to article: SkyepharmaGo to article: BaxterGo to article: CommentGo to article: Speeding up patient access to innovative drugsGo to article: The competitive landscape of neoantigen-targeting therapeutics in oncologyGo to article: Bacterial “cell factories”: an eco-friendly approach to chemical productionGo to article: MDR set to transform how MedTech firms approach content managementGo to article: PerkinElmerGo to article: NiproGo to article: NiproGo to article: In DepthGo to article: Should UK children be vaccinated against chickenpox?Go to article: Fighting India’s ‘black fungus’ epidemicGo to article: What could a vaccine patent waiver mean for pharma manufacturing? Go to article: Algae proteins: a vision of the futureGo to article: A brief history of ALS awareness and its sparse treatments Go to article: Ferring draws closer to a microbiome breakthroughGo to article: The Solubility companyGo to article: Myonex Go to article: Owen MumfordGo to article: In DataGo to article: Data: pharma subsidiaries Go to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue